Pathogen for bacterial poultry disease

Abstract

The invention belongs to the field of animal health and in particular the causative agent of a new bacterial poultry disease, Gallibacterium . The invention provides said Gallibacterium bacteria, vaccine comprising inactivated Gallibacterium , and a method of immunizing to prevent disease in poultry.

1 . Gram-negative, facultative anaerobic, pleomorphic rod-shaped bacteria causing a disease of the upper respiratory and of the reproductive tract of poultry, wherein the bacteria are selected from the group of  Pasteurella trehalosi  and  Mannheimia haemolytica.    
     
     
         2 .  Pasteurella trehalosi  or  Mannheimia haemolytica , wherein the  Pasteurella  or  Mannheimia  are beta haemolysis-positive, Gram-negative, oxidase-positive, catalase-positive, urease-negative, nitrate-positive and indole-negative. 
     
     
         3 .  Pasteurella trehalosi  or  Mannheimia haemolytica  according to  claim 2 , wherein the  Pasteurella  or  Mannheimia  are MacConkey positive. 
     
     
         4 .  Pasteurella trehalosi  or  Mannheimia haemolytica  according to  claim 2 , wherein the  Pasteurella  or  Mannheimia  are glucose-positive, sucrose-positive, mannitol-positive, arabinose-negative, celobiose-negative, xylose-positive, salicin-negative, ornithine-negative, esculin-negative, alpha-fucosidase-negative, and beta-galactosidase-positive. 
     
     
         5 .  Pasteurella trehalosi  according to  claim 2 , wherein the  Pasteurella  is Arabinose-negative and Trehalose-positive. 
     
     
         6 .  Mannheimia haemolytica  according to  claim 2 , wherein the  Mannheimia  is Arabinose-negative and Trehalose-negative. 
     
     
         7 . A method for inactivation of a  Pasteurella trehalosi  or  Mannheimia haemolytica  according to  claim 1  comprising the use of formaldehyde to a final concentration of 0.2%. 
     
     
         8 . Inactivated  Pasteurella trehalosi  or  Mannheimia haemolytica  as recited in  claim 1 . 
     
     
         9 . Inactivated  Pasteurella trehalosi  or  Mannheimia haemolytica  according to  claim 8 , wherein the  Pasteurella trehalosi  or  Mannheimia haemolytica  are selected from the group of  Pasteurella trehalosi  ATCC No. PTA-3667,  Pasteurella trehalosi  ATCC No. PTA-3668 and  Mannheimia haemolytica  ATCC No. PTA-3669. 
     
     
         10 . Live, attenuated  Pasteurella trehalosi  or  Mannheimia haemolytica  as recited in  claim 1 . 
     
     
         11 . Live, attenuated  Pasteurella trehalosi  or  Mannheimia haemolytica  according to  claim 10 , wherein the  Pasteurella trehalosi  or  Mannheimia haemolytica  are selected from the group of  Pasteurella trehalosi  ATCC No. PTA-3667,  Pasteurella trehalosi  ATCC No. PTA-3668 and  Mannheimia haemolytica  ATCC No. PTA-3669. 
     
     
         12 . Fragments or fractions containing at least one antigen of  Pasteurella trehalosi  or  Mannheimia haemolytica  according to  claim 1 . 
     
     
         13 . Fragments or fractions according to  claim 12 , wherein the fragments contain at least one antigen from bacteria selected from the group of  Pasteurella trehalosi  ATCC No. PTA-3667,  Pasteurella trehalosi  ATCC No. PTA-3668 and  Mannheimia haemolytica  ATCC No. PTA-3669. 
     
     
         14 . Vaccine composition comprising an inactivated  Pasteurella trehalosi  or  Mannheimia haemolytica  according to  claim 9 . 
     
     
         15 . Vaccine composition comprising fragments or fractions of said  Pasteurella trehalosi  or  Mannheimia haemolytica  according to  claim 12 . 
     
     
         16 . Vaccine composition comprising live, attenuated  Pasteurella trehalosi  or  Mannheimia haemolytica  according to  claim 10 . 
     
     
         17 . Vaccine composition according to  claim 14 , further comprising one or more suitable adjuvant(s) or excipient(s) or carrier(s). 
     
     
         18 . Vaccine composition according to  claim 15 , further comprising one or more suitable adjuvant(s) or excipient(s) or carrier(s). 
     
     
         19 . Vaccine composition according to  claim 18 , further comprising at least one other antigen from a virus or microorganism pathogenic to poultry. 
     
     
         20 . Vaccine composition according to  claim 16 , further comprising one or more suitable adjuvant(s) or excipient(s) or carrier(s). 
     
     
         21 . Method of diagnosis of a disease comprising the steps of obtaining a sample from poultry affected by the disease, wherein the sample is selected from the group of blood, serum, plasma, tissue scrapings, washings, swabs, and tissue, and analysing the sample for the presence of  Pasteurella trehalosi  or  Mannheimia haemolytica  as recited in  claim 1 .